NCT06594874

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

A Phase Ib Study Evaluating the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 350 (estimated)
• Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Combination With Other Anti-cancer Therapies in patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in non-Small cell lung cancer (NSCLC) .

Conditions

• Non-Small Cell Lung Cancer
• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	HS-10370	HS-10370 administered orally every day
DRUG	Adebrelimab	Administered intravenously every 21 days; dose by label.
DRUG	Cisplatin	Administered intravenously every 21 days; dose by label.
DRUG	Carboplatin	Administered intravenously every 21 days; dose by label.
DRUG	Pemetrexed	Administered intravenously every 21 days; dose by label.

Timeline

• Start date: 2024-10-31
• Primary completion: 2026-10-31
• Completion: 2027-01-01
• First posted: 2024-09-19
• Last updated: 2024-09-19

Locations

1 site across 1 country: China